• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunovant, Inc. - Common Stock (NQ:IMVT)

17.30 +0.27 (+1.59%)
Streaming Delayed Price Updated: 2:22 PM EDT, Oct 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Immunovant, Inc. - Common Stock

IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT
September 17, 2025
From Kahn Swick & Foti, LLC
Via GlobeNewswire
IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT
September 12, 2025
From Kahn Swick & Foti, LLC
Via Business Wire
IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm
August 27, 2025
From The Schall Law Firm
Via Business Wire
Immunovant Inc. (NASDAQ: IMVT) Records 52-Week High Tuesday Morning
September 26, 2023
Via Investor Brand Network
IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT
August 13, 2025
From Kahn Swick & Foti, LLC
Via Business Wire
IMVT INVESTIGATION ALERT: Pittsburgh Law Office of Alfred G. Yates Jr. PC Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm
June 20, 2025
Via ACCESS Newswire
IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm
May 21, 2025
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Immunovant Inc. (NASDAQ: IMVT) is a Stock Spotlight on 5/23
May 23, 2023
Via Investor Brand Network
Immunovant Inc. (NASDAQ: IMVT) is a Stock Spotlight on 3/24
March 24, 2023
Via Investor Brand Network
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
April 21, 2025
From Roivant Sciences
Via GlobeNewswire
Roivant Provides Update on Graves’ Disease Development Program
September 09, 2024
From Roivant Sciences
Via GlobeNewswire
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
December 20, 2023
From Roivant Sciences
Via GlobeNewswire
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
November 28, 2023
From Roivant Sciences
Via GlobeNewswire
Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th
November 07, 2022
From Immunovant Inc.
Via GlobeNewswire
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022
November 04, 2022
From Immunovant Inc.
Via GlobeNewswire
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing
October 05, 2022
Palm Beach, FL – October 5, 2022 – FinancialNewsMedia.com News Commentary – Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting for up to 4% of all... 
Via FinancialNewsMedia
Topics Death
NASDAQ:IMVT Long Term Shareholder Notice: Investigation over Possible Wrongdoing at Immunovant, Inc.
May 19, 2021
San Diego, CA -- (SBWIRE) -- 05/19/2021 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Immunovant, Inc. 
Via SBWire
Topics Lawsuit
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
April 19, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
TUESDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
April 16, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
TUESDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
April 15, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (IMVT)
April 15, 2021
From The Law Offices of Frank R. Cruz
Via Business Wire
TUESDAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
April 14, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
7-DAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
April 13, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
UPCOMING DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
April 11, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
NASDAQ:IMVT Investor Notice: Deadline on April 20, 2021 in Lawsuit Against Immunovant, Inc.
April 07, 2021
San Diego, CA -- (SBWIRE) -- 04/07/2021 -- A deadline is coming up on April 20, 2021 in the lawsuit filed for certain investors of Immunovant, Inc. (NASDAQ:IMVT). 
Via SBWire
Topics Lawsuit
UPCOMING DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
April 07, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Recent Quotes
View More
Symbol Price Change (%)
GOOG  243.62
+6.13 (2.58%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap